New immune cell combo takes on tough melanoma

NCT ID NCT05470283

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 31, 2026 · Updated 4 times

Summary

This early-phase trial tests a new treatment for people with advanced melanoma that has stopped responding to standard immunotherapy. The treatment uses a patient's own immune cells (TILs) that have been engineered to produce a protein called IL15, combined with a drug called acetazolamide. The study aims to find the safest dose and check for side effects in about 21 adults.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OBX-115 (engineered immune cells) and acetazolamide
What this could lead to: If it works, this could point toward a new treatment option for people with advanced melanoma that hasn't responded to standard immunotherapy.
What could go wrong: This is an early, small Phase 1 trial with only 21 participants, so it's mainly checking safety and dosing. The treatment may not shrink tumors or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA METASTATIC MELANOMA TUMOR

Contacts and locations

Locations

MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.